BillionToOne is trading at $98.25, up 4.03%, with no clear catalyst identified for the gain.

  • No clear company-specific catalyst explaining the October 14 move was identified.
  • BillionToOne announced it will report third-quarter results after the market close on November 4; that announcement does not establish a reason for the gain.
  • The broader market and biotech sector were both lower, so they do not explain the stock’s rise.